Monitoring blood-brain barrier (BBB) opening is of great interest in terms of brain drug delivery in the treatment of brain lymphoma and maybe in the future in other diseases like dementia. A method involving BBB disruption (BBBD) by mannitol infusion has been developed in University of Portland, USA, and then exploited in Oulu University Hospital in treatment of primary CSN lymphoma. Proper opening of the BBB is crucial for the treatment, yet there are no methods available for its real-time clinical monitoring. Recently, we presented a combined method using direct-current electroencephalography (DC-EEG) and near-infrared spectroscopy (NIRS) for monitoring BBBD in human. Carotid artery mannitol infusion generated a strongly lateralized DC-EEG response and in NIRS a prolonged increase in the oxy/deoxyhemoglobin ratio.
INTRODUCTION
The BBBD [1] by intra-arterial mannitol infusion provides first efficient treatment for otherwise lethal disease in treatment of primary CSN lymphoma (PCSNL) patients [2, 3] . Currently, other opening methods, such as, focused ultrasound (FUS) [4] and photodynamic treatment (PDT) [5] are still in preclinical development. Mannitol infusion in PCSNL patients generates a strong DC change in EEG response and a prolonged increase in the oxy/deoxyhemoglobin ratio in the brain cortex [6] . However, it is not yet clear what is the isolated role of BBBD in the observed signals, moreover, is the response of other BBB opening methods similar. In the BBBD PCSNL procedure, also very strong fluctuations in blood pressure (BP), heart rate (HR) and vascular pulsations can be observed, which are assumed to be caused mostly due to mannitol infusion. In order to optimize and improve safety of intra-arterial mannitol infusion based BBBD in clinical use controlling of cardiovascular loading during the BBBD procedure is of great interest.
Although there are studies on effects of mannitol administration on cardiovascular health, they are based only on animal data. For instance, Garcia-Sola et al. showed that infusion of mannitol in goat causes strong elevation of BP: at first, immediate rise in BP, next strong decrease and then recovering, however, to a lower BP value than pre infusion [7] . Another paper, by Gumerlock and Neuwelt, evaluates the effect of various anesthetic agents in Sprague-Dawley rats when used with mannitol. Rats were given pentobarbital, ketamine-xylazine, isoflurane, methoxyflurane, or fentanyldroperidol before intracarotid infusion of mannitol. In general, in all of these anesthetic agents, post infusion effects of mannitol were a strong decrease in BP and heart rate, and then their increase near to values pre infusion [8] . This study also suggested that the cardiovascular changes of these specific agents are important in obtaining optimal hyperosmolar BBBD.
Our aim is to develop non-invasive measurement techniques that enables monitoring effects of BBBD similarly from mouse and human. This multimodal setup can be used to optimize and improve safety of BBBD methods for clinical use, moreover, it supports enhancing the BBBD monitoring that is currently in clinical use. We will present our cardiovascular monitoring setup for mouse and human BBBD studies. Further, results show cardiovascular effects of mannitol infusion, measured from both mouse and human. Responses of HR, breathing and vascular pulsation are measured using opto-electro-mechanical sensing techniques. In addition, BP was measured on human patients invasively.
METHODOLOGY

Method of measurement
In mouse, as presented on left in Figure 1 , breathing was monitored by small opto-mechanical accelerometers placed on chest and abdomen. HR was measured both by electrocardiography (ECG) with 3 leads and by accelerometer placed on chest. Vascular pulsation (changes in arterial blood volume) was measured using a NIRS optode placed on head. Distance between the light source and detector was 5 mm. In this paper, we only show vascular pulsation, which can be also measured by a single-wavelength PPG sensor. On the other hand, by using a combination of two or three 3 wavelengths signal quality can be improved when it is disturbed by motion [9] , which we also aim to study. However, these results show vascular pulsation gathered using wavelength of 940 nm. Vascular pulsation was measured from mouse head where less motion artefacts were present.
Accelerometers can detect both HR and breathing rate, but is also very sensitive to motion artefacts. Most of the motion artefacts were apparently caused by breathing, which could be seen as a strong motion of abdomen. For this reason, breathing patterns were measured by accelerometer placed on abdomen and then by low pass filtering the signal with a cutoff frequency of 150 Hz. Using similar technique, breathing patterns can be measured also from human as presented for instance in [10] . Furthermore, HR can be measured by accelerometer placed on chest, when high-pass filtering frequencies above the frequency range of breathing.
In human, similar sensor placement for accelerometers and NIRS was used, where NIRS optode on forehead had sourcedetector distance of 3 cm. In addition, ECG, intra-arterial BP and PPG from index finger were recorded using GE DatexOhmeda S/5 Avance setup [6] . Hemodynamic responses of the NIRS signals are presented in [6] . Vascular pulsation, presented here in Figure 2 , are gathered by the PPG sensor placed on index finger. During the BBBD procedure, human patients breathing is supported by a ventilator machine thus the constant breathing patterns during anesthesia are here not presented. Figure 1 . Placement of the sensors for measuring HR, respiratory rate and vascular pulsation. Signals from mouse are measured continuously using same sensing techniques that we utilise for human measurements [10 -12] . In the middle, mannitol is injected via a catheter from external carotid into internal carotid artery under microscopy guidance. In right, human mannitol is injected to a catheter traversing via femoral artery and aorta into the internal carotid artery (red line). The catheter is placed in x-ray guided fluoroscopy [6] . In addition, BP was measured on human patients invasively (IBP). 
BBBD by intra-arterial mannitol infusion
BBBD procedure in mouse: 2-months-old mice of C57/Bl6 background were anesthetized with isoflurane (2%). External carotid artery was exposed and thin (<200 μm) heparine filled cannula was introduced into the vessel. Prewarmed 25% mannitol or 0,9% NaCl (saline) supplemented with 2% (W/V) Evans blue dye (EB) was infused into circulation in240 μl volume. The infusion rate was set to attain infusion duration of 30 sec. The infusion solutions were let to circulate for 20 min after which the animal was euthanized with overdose of Ketamine-Xylazine. The remaining EB in the vasculature was drained via contralater common carotid artery by introducing saline at the rate 500 μl/min for 10 min. EB was extracted from both hemispheres with formamide and absorbance measured with 620nm, in order to evaluate efficiency of BBBD.
Animal experiments were performed under the licence of National Animal Experiment Board of Finland (License number: Esavi/2362/04.10.07/2017 and Esavi/826/04.10.07/2018).
BBBD procedure in human:
BBBD procedure in Oulu University Hospital is based on the original procedure of Edward Neuwelt and coworkers [13, 14] . Before anaesthesia induction intravenous phenobarbital and midazolam are given. Anaesthesia is induced and maintained using propofol. Two to three minutes prior to intra-arterial mannitol infusion anaesthesia is deepened up to EEG suppression level (entropy 0) with a 250 mg intravenous thiopental bolus together with benzodiazepine. Atropine is given to counteract strong vasovagal effects of BBBD. Mannitol is given to one of the internal carotid arteries or to the dominant vertebral artery [14] . After angiographic verification of the selected artery, a hyperosmolal 25% mannitol (Hospira, Inc., Lake Forest, IL) bolus is administered intra-arterially in 30 s at an infusion rate of 4-6 ml/s, followed by 10-minute intra-arterial infusions of first methotrexate and then carboplatin (infusion rate 0.2-0.4 ml/min). Etoposide and cyclophosphamide are given intravenously 5 -10 min prior to mannitol [3, 6] .
BBBD procedures in human patients were carried out in Oulu University Hospital. Each patient was informed about data collection and signed the written consent prior to the procedure. The study was carried out in accordance with the Declaration of Helsinki and approved by the Ethical Committee of Northern Ostrobothnia Hospital District, Oulu University Hospital (number 5/2014). Figure 2 shows typical cardiovascular effects monitored during the human BBBD by intra-arterial mannitol infusion [3, 6] . 
RESULTS
DISCUSSION
Here we show that similar opto-electro-mechanical sensors that are used in humans can also be applied to mice. However, due to small body size optimal positioning of the sensors and shaving of skin areas was crusial for detecting low amplitude oscillations. With proper filtering and by utilizing several sensors, placed on chest, abdomen and head, we were able to reduce motion artefacts and dissect oscillations emerging from respiration, heartbeats and blood pulsations.
Typically, mannitol injection induced identical response to human data (as presented in Figures 2 and 3) . However, mouse vital functions showed noticeable variation between individuals. We think this is due to variable effect of isoflurane anesthesia to vascular tone. Isoflurane slows down the respiration rate [15] , causes hypercapnia and cerebral vasodilation [16, 17] . We see individual variation in baseline respiration rate this being generally lower than 50 cycles/min. Interestingly, some individuals with low baseline respiration rate developed tachycardia following mannitol bolus. Due to its variable effects on vascular tone and dampening influence on BBBD isoflurane is not preferred anesthetic in rats and humans [16] . However, we were able to induce significant BBBD reproducibly by using isoflurane and prefer its use due to its fast and effective anesthesia and easiness of post-anesthetic recovery.
